- Anti-aging concern Unity Biotechnology, Inc. saw its share price collapse after its lead candidate (UBX0101) flunked a Phase 2 study in August 2020.
- The setback forced a restructuring with a pivot away from musculoskeletal targets and towards ophthalmologic and neurologic indications.
- With one early-stage clinical asset, a greater than 100% rebound off its post-clinical-failure lows, and a cash runway into mid-2022, this busted IPO warranted additional investigation.
- A full investment analysis follows below.
For further details see:
Our First Take On Unity Biotechnology